Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome

Endocrine

Volumn 48, Issue 1, 2015, Pages 65-68

  Bruyère, Olivier ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antidepressants; Depression; Fracture; Osteoporosis; Selective serotonin reuptake inhibitors

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DEPRESSION; FRACTURES, BONE; HUMAN; OSTEOPOROSIS;

ANIMALS; DEPRESSION; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; SEROTONIN UPTAKE INHIBITORS;

EID: 84929082431     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0357-0     Document Type: Review

References (31)

1. E.S. Paykel, Depression: major problem for public health. Epidemiol. Psichiatr. Soc. 15(1), 4–10 (2006)
2. R.S. Shim, P. Baltrus, J. Ye, G. Rust, Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005–2008. J. Am. Board Fam. Med. 24(1), 33–38 (2011). doi:10.3122/jabfm.2011.01.100121
3. J. Alonso, M.C. Angermeyer, S. Bernert, R. Bruffaerts, T.S. Brugha, H. Bryson, G. de Girolamo, R. Graaf, K. Demyttenaere, I. Gasquet, J.M. Haro, S.J. Katz, R.C. Kessler, V. Kovess, J.P. Lepine, J. Ormel, G. Polidori, L.J. Russo, G. Vilagut, J. Almansa, S. Arbabzadeh-Bouchez, J. Autonell, M. Bernal, M.A. Buist-Bouwman, M. Codony, A. Domingo-Salvany, M. Ferrer, S.S. Joo, M. Martinez-Alonso, H. Matschinger, F. Mazzi, Z. Morgan, P. Morosini, C. Palacin, B. Romera, N. Taub, W.A. Vollebergh, Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. 190(s420), 21–27 (2004). doi:10.1111/j.1600-0047.2004.00327.x
4. M. Moore, H.M. Yuen, N. Dunn, M.A. Mullee, J. Maskell, T. Kendrick, Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 339, b3999 (2009). doi:10.1136/bmj.b3999
5. P. Lockhart, B. Guthrie, Trends in primary care antidepressant prescribing 1995–2007: a longitudinal population database analysis. Br. J. Gen. Pract. 61(590), e565–e572 (2011). doi:10.3399/bjgp11X593848
6. R. Rizzoli, C. Cooper, J.Y. Reginster, B. Abrahamsen, J.D. Adachi, M.L. Brandi, O. Bruyere, J. Compston, P. Ducy, S. Ferrari, N.C. Harvey, J.A. Kanis, G. Karsenty, A. Laslop, V. Rabenda, P. Vestergaard, Antidepressant medications and osteoporosis. Bone 51(3), 606–613 (2012). doi:10.1016/j.bone.2012.05.018
7. O. Spigset, B. Martensson, Fortnightly review: drug treatment of depression. BMJ 318(7192), 1188–1191 (1999)
8. E.M. Haney, S.J. Warden, M.M. Bliziotes, Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 46(1), 13–17 (2010). doi:10.1016/j.bone.2009.07.083
9. P. Ducy, G. Karsenty, The two faces of serotonin in bone biology. J. Cell Biol. 191(1), 7–13 (2010). doi:10.1083/jcb.201006123
10. E.M. Haney, S.J. Warden, Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J. Musculoskelet. Neuronal Interact. 8(2), 133–145 (2008)
11. S.J. Diem, T.L. Blackwell, K.L. Stone, K. Yaffe, E.M. Haney, M.M. Bliziotes, K.E. Ensrud, Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch. Intern. Med. 167(12), 1240–1245 (2007). doi:10.1001/archinte.167.12.1240
12. L.J. Williams, M.J. Henry, M. Berk, S. Dodd, F.N. Jacka, M.A. Kotowicz, G.C. Nicholson, J.A. Pasco, Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int. Clin. Psychopharmacol. 23(2), 84–87 (2008). doi:10.1097/YIC.0b013e3282f2b3bb
13. E.M. Haney, B.K. Chan, S.J. Diem, K.E. Ensrud, J.A. Cauley, E. Barrett-Connor, E. Orwoll, M.M. Bliziotes, Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med. 167(12), 1246–1251 (2007). doi:10.1001/archinte.167.12.1246
14. R. Ginzburg, E. Rosero, Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants. Ann. Pharmacother. 43(1), 98–103 (2009). doi:10.1345/aph.1L264
15. S. Schwan, P. Hallberg, SSRIs, bone mineral density, and risk of fractures—a review. Eur. Neuropsychopharmacol. 19(10), 683–692 (2009). doi:10.1016/j.euroneuro.2009.05.001
16. V. Rabenda, O. Bruyere, J.Y. Reginster, Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. Bone 51(4), 674–679 (2012). doi:10.1016/j.bone.2012.07.030
17. M.S. Bakken, A. Engeland, L.B. Engesaeter, A.H. Ranhoff, S. Hunskaar, S. Ruths, Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 42(4), 514–520 (2013). doi:10.1093/ageing/aft009
18. D. Prieto-Alhambra, H. Petri, J.S. Goldenberg, T.P. Khong, O.H. Klungel, N.J. Robinson, F. de Vries, Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA. Osteoporos. Int. 25(3), 847–855 (2014). doi:10.1007/s00198-013-2612-2
19. C. Moura, S. Bernatsky, M. Abrahamowicz, A. Papaioannou, L. Bessette, J. Adachi, D. Goltzman, J. Prior, N. Kreiger, T. Towheed, W.D. Leslie, S. Kaiser, G. Ioannidis, L. Pickard, L.A. Fraser, E. Rahme, Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos. Int. 25(5), 1473–1481 (2014). doi:10.1007/s00198-014-2649-x
20. J.J. Gagne, A.R. Patrick, H. Mogun, D.H. Solomon, Antidepressants and fracture risk in older adults: a comparative safety analysis. Clin. Pharmacol. Ther. 89(6), 880–887 (2011). doi:10.1038/clpt.2011.54
21. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012). doi:10.1007/s12020-011-9570-2
22. J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42(1), 39–51 (2012). doi:10.1007/s12020-012-9691-2
23. Q. Wu, W. Qu, M.D. Crowell, J.G. Hentz, K.A. Frey, Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies. J. Bone Miner. Res. 28(4), 753–763 (2013). doi:10.1002/jbmr.1813
24. V. Rabenda, D. Nicolet, C. Beaudart, O. Bruyere, J.Y. Reginster, Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos. Int. 24(1), 121–137 (2013). doi:10.1007/s00198-012-2015-9
25. C.S. Eom, H.K. Lee, S. Ye, S.M. Park, K.H. Cho, Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J. Bone Miner. Res 27(5), 1186–1195 (2012). doi:10.1002/jbmr.1554
26. L.H. Oderda, J.R. Young, C.V. Asche, G.A. Pepper, Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann. Pharmacother. 46(7–8), 917–928 (2012). doi:10.1345/aph.1Q589
27. J.Y. Reginster, R. Deroisy, I. Paul, M. Hansenne, M. Ansseau, Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas 33(2), 133–137 (1999)
28. C.V. Phillips, K.J. Goodman, The missed lessons of Sir Austin Bradford Hill. Epidemiol. Perspect. Innov. 1(1), 3 (2004). doi:10.1186/1742-5573-1-3
29. M.W. van den Brand, S. Pouwels, M.M. Samson, T.P. van Staa, B. Thio, C. Cooper, H.G. Leufkens, A.C. Egberts, H.J. Verhaar, F. de Vries, Use of anti-depressants and the risk of fracture of the hip or femur. Osteopor. Int. 20(10), 1705–1713 (2009). doi:10.1007/s00198-009-0849-6
30. P. Vestergaard, D. Prieto-Alhambra, M.K. Javaid, C. Cooper, Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos. Int. 24(2), 671–680 (2013). doi:10.1007/s00198-012-2043-5
31. J.M. Robine, E. Cambois, W. Nusselder, B. Jeune, H.V. Oyen, C. Jagger, The joint action on healthy life years (JA: EHLEIS). Arch. Public Health 71(1), 2 (2013). doi:10.1186/0778-7367-71-2